Onconova Therapeutics, Inc. (ONTX)

NASDAQ: ONTX · IEX Real-Time Price · USD
0.690
+0.014 (2.12%)
At close: Feb 23, 2024, 4:00 PM
0.670
-0.020 (-2.90%)
After-hours: Feb 23, 2024, 7:55 PM EST
2.12%
Market Cap 14.49M
Revenue (ttm) 226,000
Net Income (ttm) -20.18M
Shares Out 21.00M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 43,282
Open 0.677
Previous Close 0.676
Day's Range 0.677 - 0.700
52-Week Range 0.550 - 1.450
Beta 1.34
Analysts Strong Buy
Price Target 11.00 (+1,494.2%)
Earnings Date Mar 14, 2024

About ONTX

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2013
Employees 16
Stock Exchange NASDAQ
Ticker Symbol ONTX
Full Company Profile

Financial Performance

In 2022, ONTX's revenue was $226,000, a change of 0.00% compared to the previous year's $226,000. Losses were -$18.96 million, 17.3% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ONTX stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(1,494.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa...

2 months ago - GlobeNewsWire

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developin...

3 months ago - GlobeNewsWire

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational ...

3 months ago - GlobeNewsWire

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develop...

3 months ago - GlobeNewsWire

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models

4 months ago - GlobeNewsWire

Onconova Expands Leadership Team with Two Key Appointments

Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX...

4 months ago - GlobeNewsWire

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers

4 months ago - GlobeNewsWire

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...

5 months ago - GlobeNewsWire

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...

6 months ago - GlobeNewsWire

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care Narazaciclib ...

9 months ago - GlobeNewsWire

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa Trial in Progr...

9 months ago - GlobeNewsWire

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) --   Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...

10 months ago - GlobeNewsWire

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m.

10 months ago - GlobeNewsWire

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023

10 months ago - GlobeNewsWire

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...

11 months ago - GlobeNewsWire

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Collaboration builds off clinical data demonstrating rigosertib's activity against PLK1 and may inform a precision medicine approach towards rigosertib's evaluation in new indications

1 year ago - GlobeNewsWire

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

1 year ago - GlobeNewsWire

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023

1 year ago - GlobeNewsWire

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations

1 year ago - GlobeNewsWire

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin le...

1 year ago - GlobeNewsWire

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel product...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...

1 year ago - GlobeNewsWire